Bladder cancer remains a leading cause of cancer death worldwide and is associated with
substantial impacts on patient quality of life, morbidity, mortality, and cost to the healthcare …

Bladder cancer (BC) can be divided into two subgroups depending on invasion of the
muscular layer: non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder …

Abstract N6-Methyladenosine (m6A) is the most prevalent internal modification of
mammalian mRNAs. Recent studies have shown that m6A methyltransferases METTL3 and …

Background The functional status of immune cells in the tumor microenvironment and tumor
characteristics may explain bacillus Calmette-Guérin (BCG) failure in high-risk non–muscle …

Introduction Since 2016, the progressive use of immune checkpoint inhibitors (ICIs) starting
from second-line treatment has led to an improvement in overall survival in locally advanced …

Molecular subty** has been a major focus of bladder cancer research over the past
decade. Despite many promising associations with clinical outcomes and treatment …

Background Three-quarters of bladder cancer patients present with early-stage disease
(non-muscle-invasive bladder cancer, NMIBC, UICC TNM stages Ta, T1 and Tis); however …

Simple Summary Bladder cancer (BC) is a common cancer that causes high morbidity and
mortality among affected patients. As a carcinogen-driven cancer, molecular oncology of BC …

We aimed to investigate the genomic and tumor microenvironmental (TME) profiles in non-
muscle invasive bladder cancer (NMIBC) and explore potential predictive markers for …

The field of immuno-oncology is now at the forefront of cancer care and is rapidly evolving.
The immune checkpoint blockade has been demonstrated to restore antitumor responses in …